Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial. Journal Article

Local Library Link: Find It @ Loyola

Authors: Halaris, A; Cantos, A; Johnson, K; Hakimi, M; Sinacore, J
Article Title: Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial.
Abstract: OBJECTIVE: The goal of this study was to reduce treatment resistance and enhance antidepressant response in patients with treatment-resistant bipolar depression (TRBDD) by modulating inflammatory activation. METHODS: Forty-seven TRBDD patients completed a randomized, double-blind, placebo (PBO)-controlled two-arm study using celecoxib (CBX), a cyclooxygenase 2 (COX-2) inhibitor, in combination with escitalopram (ESC). The Hamilton Depression (17-Item) and the Hamilton Anxiety Rating Scales were used to quantify symptom severity. Self-rating instruments included BDI, BAI and QLES-Q questioner. An adverse events inventory was used, and the possibility of bleeding diathesis was monitored. Complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (APTT) were determined. Comparison of mood scores between the CBX and PBO groups were conducted using a mixed ANOVA and an Independent Sample Student t-test. RESULTS: The CBX adjunctive treatment produced significantly more responders and remitters than the PBO arm. Compared to the PBO group (n?=?20), the CBX group (n?=?27) experienced lower depression severity through the entire course of the study, showing significant decrease in depression and anxiety scores as early as week 1. Except for initial mild nausea, no adverse events were reported and study medications were well tolerated. CONCLUSIONS: Modulation of the inflammatory response through targeted inhibition of the enzyme COX-2 by means of CBX reduces TRBDD and augments and accelerates treatment response in an efficacious and safe manner. Future studies should replicate these findings and additionally investigate whether prolonged administration of CBX is required to maintain remission by adding a discontinuation phase to the study design. TRIAL REGISTRATION: Clinicaltrials.gov ID: NCT01479829.
Journal Title: JOURNAL OF AFFECTIVE DISORDERS
Publisher: Unknown  
Date Published: 2019